enVVeno Medical Executes One-for-35 Reverse Stock Split

enVVeno Medical ( (NVNO) ) just unveiled an update.

On January 20, 2026, enVVeno Medical Corporation implemented a one-for-35 reverse stock split of its common stock, combining every 35 issued and outstanding shares into one share without changing the par value, and rounding any fractional shares up to the nearest whole share. The move, approved by both the board and stockholders, reduced the number of shares outstanding from 22,946,223 to 655,606, triggered proportional adjustments to outstanding options and warrants, and led the stock to begin trading on a split-adjusted basis the same day, significantly consolidating the company’s equity base while leaving its authorized share count unchanged.

The most recent analyst rating on (NVNO) stock is a Sell with a $0.32 price target. To see the full list of analyst forecasts on enVVeno Medical stock, see the NVNO Stock Forecast page.

Spark’s Take on NVNO Stock

According to Spark, TipRanks’ AI Analyst, NVNO is a Neutral.

The score is driven primarily by weak financial performance (no revenue, sizable losses, and continued cash burn), compounded by a bearish technical setup (price below all key moving averages and negative MACD). Negative corporate events (FDA setback and Nasdaq bid-price compliance risk) add further downside risk, while valuation support is limited due to negative earnings and no indicated dividend.

To see Spark’s full report on NVNO stock, click here.

More about enVVeno Medical

enVVeno Medical Corporation operates in the medical sector and is listed with common stock issued under a Delaware corporate structure, with a large authorized share base of 250 million shares that supports its capital markets activities.

Average Trading Volume: 592,760

Technical Sentiment Signal: Sell

Current Market Cap: $6.91M

See more insights into NVNO stock on TipRanks’ Stock Analysis page.